Role of non-neuronal nicotinic acetylcholine receptors in angiogenesis modulation

Shaker A. Mousa, Hugo R. Arias, Paul J. Davis

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)

Abstract

Angiogenesis is a critical physiological process for cell survival and development. Endothelial cells, necessary for the course of angiogenesis, express several non-neuronal nicotinic acetylcholine receptors (AChRs). The most important functional non-neuronal AChRs are homomeric α7 AChRs and several heteromeric AChRs formed by a combination of α3, α5, β2, and β4 subunits, including α3β4-containing AChRs. In endothelial cells, α7 AChR stimulation indirectly triggers the activation of the integrin αvβ3 receptor and an intracellular MAP kinase (ERK) pathway that mediates angiogenesis. Non-selective cholinergic agonists such as nicotine have been shown to induce angiogenesis, enhancing tumor progression. Moreover, α7 AChR selective antagonists such as α-bungarotoxin and methyllycaconitine as well as the nonspecific antagonist mecamylamine have been shown to inhibit endothelial cell proliferation and ultimately blood vessel formation. Exploitation of such pharmacologic properties can lead to the discovery of new specific cholinergic antagonists as anti-cancer therapies. Conversely, the pro-angiogenic effect elicited by specific agonists can be used to treat diseases that respond to revascularization such as diabetic ischemia and foot ulcer, as well as to accelerate wound-healing. In this chapter we discuss the pharmacological evidence supporting the importance of non-neuronal AChRs in angiogenesis. We also explore potential intracellular mechanisms by which α7 AChR activation mediates this vital cellular process.

Original languageEnglish
Title of host publicationAngiogenesis Modulations in Health and Disease
Subtitle of host publicationPractical Applications of Pro- and Anti-angiogenesis Targets
PublisherSpringer Netherlands
Pages55-75
Number of pages21
ISBN (Electronic)9789400764675
ISBN (Print)9400764669, 9789400764668
DOIs
StatePublished - 1 Nov 2013
Externally publishedYes

Fingerprint

Nicotinic Receptors
Cholinergic Receptors
Endothelial Cells
Physiological Phenomena
Mecamylamine
Bungarotoxins
Cholinergic Agonists
Diabetic Foot
MAP Kinase Signaling System
Cholinergic Antagonists
Nicotine
Integrins
Wound Healing
Blood Vessels
Neoplasms
Cell Survival
Phosphotransferases
Ischemia
Cell Proliferation
Pharmacology

Cite this

Mousa, S. A., Arias, H. R., & Davis, P. J. (2013). Role of non-neuronal nicotinic acetylcholine receptors in angiogenesis modulation. In Angiogenesis Modulations in Health and Disease: Practical Applications of Pro- and Anti-angiogenesis Targets (pp. 55-75). Springer Netherlands. https://doi.org/10.1007/978-94-007-6467-5_6
Mousa, Shaker A. ; Arias, Hugo R. ; Davis, Paul J. / Role of non-neuronal nicotinic acetylcholine receptors in angiogenesis modulation. Angiogenesis Modulations in Health and Disease: Practical Applications of Pro- and Anti-angiogenesis Targets. Springer Netherlands, 2013. pp. 55-75
@inbook{a21ef9da645742d9a9feb80c99f8b958,
title = "Role of non-neuronal nicotinic acetylcholine receptors in angiogenesis modulation",
abstract = "Angiogenesis is a critical physiological process for cell survival and development. Endothelial cells, necessary for the course of angiogenesis, express several non-neuronal nicotinic acetylcholine receptors (AChRs). The most important functional non-neuronal AChRs are homomeric α7 AChRs and several heteromeric AChRs formed by a combination of α3, α5, β2, and β4 subunits, including α3β4-containing AChRs. In endothelial cells, α7 AChR stimulation indirectly triggers the activation of the integrin αvβ3 receptor and an intracellular MAP kinase (ERK) pathway that mediates angiogenesis. Non-selective cholinergic agonists such as nicotine have been shown to induce angiogenesis, enhancing tumor progression. Moreover, α7 AChR selective antagonists such as α-bungarotoxin and methyllycaconitine as well as the nonspecific antagonist mecamylamine have been shown to inhibit endothelial cell proliferation and ultimately blood vessel formation. Exploitation of such pharmacologic properties can lead to the discovery of new specific cholinergic antagonists as anti-cancer therapies. Conversely, the pro-angiogenic effect elicited by specific agonists can be used to treat diseases that respond to revascularization such as diabetic ischemia and foot ulcer, as well as to accelerate wound-healing. In this chapter we discuss the pharmacological evidence supporting the importance of non-neuronal AChRs in angiogenesis. We also explore potential intracellular mechanisms by which α7 AChR activation mediates this vital cellular process.",
author = "Mousa, {Shaker A.} and Arias, {Hugo R.} and Davis, {Paul J.}",
year = "2013",
month = "11",
day = "1",
doi = "10.1007/978-94-007-6467-5_6",
language = "English",
isbn = "9400764669",
pages = "55--75",
booktitle = "Angiogenesis Modulations in Health and Disease",
publisher = "Springer Netherlands",
address = "Netherlands",

}

Mousa, SA, Arias, HR & Davis, PJ 2013, Role of non-neuronal nicotinic acetylcholine receptors in angiogenesis modulation. in Angiogenesis Modulations in Health and Disease: Practical Applications of Pro- and Anti-angiogenesis Targets. Springer Netherlands, pp. 55-75. https://doi.org/10.1007/978-94-007-6467-5_6

Role of non-neuronal nicotinic acetylcholine receptors in angiogenesis modulation. / Mousa, Shaker A.; Arias, Hugo R.; Davis, Paul J.

Angiogenesis Modulations in Health and Disease: Practical Applications of Pro- and Anti-angiogenesis Targets. Springer Netherlands, 2013. p. 55-75.

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Role of non-neuronal nicotinic acetylcholine receptors in angiogenesis modulation

AU - Mousa, Shaker A.

AU - Arias, Hugo R.

AU - Davis, Paul J.

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Angiogenesis is a critical physiological process for cell survival and development. Endothelial cells, necessary for the course of angiogenesis, express several non-neuronal nicotinic acetylcholine receptors (AChRs). The most important functional non-neuronal AChRs are homomeric α7 AChRs and several heteromeric AChRs formed by a combination of α3, α5, β2, and β4 subunits, including α3β4-containing AChRs. In endothelial cells, α7 AChR stimulation indirectly triggers the activation of the integrin αvβ3 receptor and an intracellular MAP kinase (ERK) pathway that mediates angiogenesis. Non-selective cholinergic agonists such as nicotine have been shown to induce angiogenesis, enhancing tumor progression. Moreover, α7 AChR selective antagonists such as α-bungarotoxin and methyllycaconitine as well as the nonspecific antagonist mecamylamine have been shown to inhibit endothelial cell proliferation and ultimately blood vessel formation. Exploitation of such pharmacologic properties can lead to the discovery of new specific cholinergic antagonists as anti-cancer therapies. Conversely, the pro-angiogenic effect elicited by specific agonists can be used to treat diseases that respond to revascularization such as diabetic ischemia and foot ulcer, as well as to accelerate wound-healing. In this chapter we discuss the pharmacological evidence supporting the importance of non-neuronal AChRs in angiogenesis. We also explore potential intracellular mechanisms by which α7 AChR activation mediates this vital cellular process.

AB - Angiogenesis is a critical physiological process for cell survival and development. Endothelial cells, necessary for the course of angiogenesis, express several non-neuronal nicotinic acetylcholine receptors (AChRs). The most important functional non-neuronal AChRs are homomeric α7 AChRs and several heteromeric AChRs formed by a combination of α3, α5, β2, and β4 subunits, including α3β4-containing AChRs. In endothelial cells, α7 AChR stimulation indirectly triggers the activation of the integrin αvβ3 receptor and an intracellular MAP kinase (ERK) pathway that mediates angiogenesis. Non-selective cholinergic agonists such as nicotine have been shown to induce angiogenesis, enhancing tumor progression. Moreover, α7 AChR selective antagonists such as α-bungarotoxin and methyllycaconitine as well as the nonspecific antagonist mecamylamine have been shown to inhibit endothelial cell proliferation and ultimately blood vessel formation. Exploitation of such pharmacologic properties can lead to the discovery of new specific cholinergic antagonists as anti-cancer therapies. Conversely, the pro-angiogenic effect elicited by specific agonists can be used to treat diseases that respond to revascularization such as diabetic ischemia and foot ulcer, as well as to accelerate wound-healing. In this chapter we discuss the pharmacological evidence supporting the importance of non-neuronal AChRs in angiogenesis. We also explore potential intracellular mechanisms by which α7 AChR activation mediates this vital cellular process.

UR - http://www.scopus.com/inward/record.url?scp=84911492954&partnerID=8YFLogxK

U2 - 10.1007/978-94-007-6467-5_6

DO - 10.1007/978-94-007-6467-5_6

M3 - Chapter

AN - SCOPUS:84911492954

SN - 9400764669

SN - 9789400764668

SP - 55

EP - 75

BT - Angiogenesis Modulations in Health and Disease

PB - Springer Netherlands

ER -

Mousa SA, Arias HR, Davis PJ. Role of non-neuronal nicotinic acetylcholine receptors in angiogenesis modulation. In Angiogenesis Modulations in Health and Disease: Practical Applications of Pro- and Anti-angiogenesis Targets. Springer Netherlands. 2013. p. 55-75 https://doi.org/10.1007/978-94-007-6467-5_6